The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

subcutaneous group: short acting, 24.0 and 25.5 units, respectively, and intermediate acting, 50.1 and 52.3 units, respectively). As the inhaled insulin regimen involved only one daily injection ...

Regular insulin, which is often used in pregnancy for the treatment of diabetes, has some drawbacks: it starts its action from 30 to 60 min after subcutaneous injection and it peaks too late (2-3 ...

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

This human insulin analogue that comes in disposable pens prefilled ... Steady state is achieved after 3–4 weekly subcutaneous injections.

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Insulin pump market growth is propelled by advancements in technology, rising global diabetes prevalence, and increased demand for precision diabetes management.New Delhi, Feb. 06, 2025 (GLOBE ...

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...